Topiramate (Epilepsy)

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7662
R22679		 Tomson (Topiramate), 2018 Cleft lip or palate at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 2.37 [0.12;46.04] C 0/152   3/2,514 3 152
ref
S6061
R15759		 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Facial cleft 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 23.93 [1.46;392.85] C 1/28   1/647 2 28
ref
Total 2 studies 7.95 [0.83;76.53] 5 180
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Topiramate), 2018Tomson, 2018 1 2.37[0.12; 46.04]315248%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 23.93[1.46; 392.85]22852%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 19% 7.95[0.83; 76.53]51800.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate; 2: Topiramate) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 7.95[0.83; 76.53]518019%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 7.95[0.83; 76.53]518019%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 Tags Adjustment   - No  - No 7.95[0.83; 76.53]518019%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 7.95[0.83; 76.53]518019%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 7.95[0.83; 76.53]518019%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0